Pub Date : 2024-10-18eCollection Date: 2024-10-01DOI: 10.32481/djph.2024.10.03
Ross A Thompson
Early brain development research is important to public health professionals for understanding early development and strengthening systemic supports for young children's healthy brain growth. This overview describes basic processes of early brain development, including prenatal development and the "fetal programming" of brain and behavior, neural proliferation and the essential influence of experience in the creation of neural networks, the maturational timing of different brain systems and their behavioral consequences, the myelination of neural pathways and its influence on children's action and thinking, and the capacity of the brain to create new neural connections throughout life, which contributes to its continuing adaptability to new experiences. The implications of this research for public health and for strengthening support for early brain development are considered throughout this discussion.
{"title":"Early Brain Development and Public Health.","authors":"Ross A Thompson","doi":"10.32481/djph.2024.10.03","DOIUrl":"10.32481/djph.2024.10.03","url":null,"abstract":"<p><p>Early brain development research is important to public health professionals for understanding early development and strengthening systemic supports for young children's healthy brain growth. This overview describes basic processes of early brain development, including prenatal development and the \"fetal programming\" of brain and behavior, neural proliferation and the essential influence of experience in the creation of neural networks, the maturational timing of different brain systems and their behavioral consequences, the myelination of neural pathways and its influence on children's action and thinking, and the capacity of the brain to create new neural connections throughout life, which contributes to its continuing adaptability to new experiences. The implications of this research for public health and for strengthening support for early brain development are considered throughout this discussion.</p>","PeriodicalId":72774,"journal":{"name":"Delaware journal of public health","volume":"10 4","pages":"6-11"},"PeriodicalIF":0.0,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-10-18eCollection Date: 2024-10-01DOI: 10.32481/djph.2024.10.10
Priscilla Mpasi
{"title":"A Child's Health Begins at Pregnancy, Requires Solid Early Investments, and Follows a Child into Adulthood.","authors":"Priscilla Mpasi","doi":"10.32481/djph.2024.10.10","DOIUrl":"https://doi.org/10.32481/djph.2024.10.10","url":null,"abstract":"","PeriodicalId":72774,"journal":{"name":"Delaware journal of public health","volume":"10 4","pages":"30"},"PeriodicalIF":0.0,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11526691/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-28eCollection Date: 2024-08-01DOI: 10.32481/djph.2024.08.06
Kendra Flores
{"title":"Hereditary Cancer Genetic Testing: 30 Years of Impact on Cancer Care.","authors":"Kendra Flores","doi":"10.32481/djph.2024.08.06","DOIUrl":"https://doi.org/10.32481/djph.2024.08.06","url":null,"abstract":"","PeriodicalId":72774,"journal":{"name":"Delaware journal of public health","volume":"10 3","pages":"16-20"},"PeriodicalIF":0.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11356586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-28eCollection Date: 2024-08-01DOI: 10.32481/djph.2024.08.09
Susan Birkhoff, Heidi Donovan, Young Ji Lee
Purpose: The purpose of this study was to 1) describe oncology caregivers' pre-treatment preparation experiences, 2) elicit their feedback about approaches to improve the pre-treatment preparation experience, and 3) explore the potential use of visual aids into the pre-treatment education experience that will inform future clinician-led VR experiences.
Methods: Using a qualitative descriptive design and convenience sampling technique, adult oncology caregivers were recruited to complete anonymous demographic and qualitative surveys posted on social media sites (i.e. American Cancer Society, Facebook, and LinkedIn) and a university supported community research registry (i.e. Pitt + Me). Demographic data were calculated using descriptive analyses (frequency and percentage) and qualitative data were analyzed using an inductive coding approach.
Results: Participants (N=18) were mostly female (n=13, 72%), white (n=14, 78%), married (n=14, 78%), and had a college degree or higher (n=16, 89%). They categorically ranged in age from 26 years to above 65 years, with the majority (n=11, 61%) between 36-55 years of age. Caregivers described the cancer information as overwhelming and in need of additional side effect information and emotional support. To meet their unmet needs, participants suggested providing additional resources, different approaches to learning, better explanation of processes and procedures, diverse emotional support, and more interactions with the oncology team.
Conclusion: Clinician created VR experiences designed for and informed by oncology caregivers do not exist yet. VR could provide an alternative pediogogical approach to complement standard oncology treatment preparation. These study findings begin the exploration into innovative preparation approaches that could meet oncology caregivers' unmet emotional and educational needs during a stressful period.
Key highlights: There is a dearth of clinicians creating and testing VR experiences for patients, let alone caregivers. Oncology caregivers are the unseen 'backbone' supporting their loved one and providing an innovative modality to support them could improve outcomes. VR has the potential improve outcomes for caregivers, which may improve outcomes for patients.
{"title":"Informing a Future Clinician-Led Virtual Reality Experience Through Oncology Caregivers' Pre-Treatment Preparation Experiences.","authors":"Susan Birkhoff, Heidi Donovan, Young Ji Lee","doi":"10.32481/djph.2024.08.09","DOIUrl":"https://doi.org/10.32481/djph.2024.08.09","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this study was to 1) describe oncology caregivers' pre-treatment preparation experiences, 2) elicit their feedback about approaches to improve the pre-treatment preparation experience, and 3) explore the potential use of visual aids into the pre-treatment education experience that will inform future clinician-led VR experiences.</p><p><strong>Methods: </strong>Using a qualitative descriptive design and convenience sampling technique, adult oncology caregivers were recruited to complete anonymous demographic and qualitative surveys posted on social media sites (i.e. American Cancer Society, Facebook, and LinkedIn) and a university supported community research registry (i.e. Pitt + Me). Demographic data were calculated using descriptive analyses (frequency and percentage) and qualitative data were analyzed using an inductive coding approach.</p><p><strong>Results: </strong>Participants (N=18) were mostly female (n=13, 72%), white (n=14, 78%), married (n=14, 78%), and had a college degree or higher (n=16, 89%). They categorically ranged in age from 26 years to above 65 years, with the majority (n=11, 61%) between 36-55 years of age. Caregivers described the cancer information as overwhelming and in need of additional side effect information and emotional support. To meet their unmet needs, participants suggested providing additional resources, different approaches to learning, better explanation of processes and procedures, diverse emotional support, and more interactions with the oncology team.</p><p><strong>Conclusion: </strong>Clinician created VR experiences designed for and informed by oncology caregivers do not exist yet. VR could provide an alternative pediogogical approach to complement standard oncology treatment preparation. These study findings begin the exploration into innovative preparation approaches that could meet oncology caregivers' unmet emotional and educational needs during a stressful period.</p><p><strong>Key highlights: </strong>There is a dearth of clinicians creating and testing VR experiences for patients, let alone caregivers. Oncology caregivers are the unseen 'backbone' supporting their loved one and providing an innovative modality to support them could improve outcomes. VR has the potential improve outcomes for caregivers, which may improve outcomes for patients.</p>","PeriodicalId":72774,"journal":{"name":"Delaware journal of public health","volume":"10 3","pages":"30-35"},"PeriodicalIF":0.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11356583/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-28eCollection Date: 2024-08-01DOI: 10.32481/djph.2024.08.05
Valerie Lim, Stephen C Eppes
Vaccines play an import role in cancer prevention as well as a growing role in cancer therapeutics. This article explores current knowledge regarding the role of vaccines (HPV and HBV vaccines) in protecting against preventable risk factors for select cancers as well as anti-cancer vaccines currently being used in practice. Current data suggests that routine childhood vaccination against HPV and HBV is an effective strategy for not only protecting against life-altering infectious diseases but also protecting against adult-onset cancers. Furthermore, while current vaccination practices and anti-cancer therapeutics have come a long way in recent decades, examination of CDC data also identifies areas for growth and improvement.
{"title":"Vaccines: An Emerging Multi-Modal Tool in the Fight Against Cancer.","authors":"Valerie Lim, Stephen C Eppes","doi":"10.32481/djph.2024.08.05","DOIUrl":"https://doi.org/10.32481/djph.2024.08.05","url":null,"abstract":"<p><p>Vaccines play an import role in cancer prevention as well as a growing role in cancer therapeutics. This article explores current knowledge regarding the role of vaccines (HPV and HBV vaccines) in protecting against preventable risk factors for select cancers as well as anti-cancer vaccines currently being used in practice. Current data suggests that routine childhood vaccination against HPV and HBV is an effective strategy for not only protecting against life-altering infectious diseases but also protecting against adult-onset cancers. Furthermore, while current vaccination practices and anti-cancer therapeutics have come a long way in recent decades, examination of CDC data also identifies areas for growth and improvement.</p>","PeriodicalId":72774,"journal":{"name":"Delaware journal of public health","volume":"10 3","pages":"12-14"},"PeriodicalIF":0.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11356588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142116939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-28eCollection Date: 2024-08-01DOI: 10.32481/djph.2024.08.07
Brian Nam, Danny Hamm, Nora Katurakes, Charles Mulligan
Lung cancer remains the number one cancer related mortality in the United States . While it is the third most diagnosed cancer, it is often found at an advanced stage. Survival rates for stage I lung cancer are above 70% while survival rates for stage IV lung cancer are less than 10% at five years. Methods to detect lung cancer at an earlier stage when it can be more effectively treated have been investigated for many years. These included regular chest x-rays (CXRs) and sputum samples. Unfortunately, these testing modalities did not show any benefit. This changed in 2011 when data from the National Lung Screening Trial were published. This landmark trial showed conclusively that a low-radiation dose chest computed tomography scan (LDCT) performed annually in patients with a heavy smoking history reduced lung cancer related mortality by 20%. These results have led to a nationwide effort to increase lung cancer screening. While the number of eligible patients that are being screened on a national level remains modest, significant efforts are being made at the state and local levels to increase awareness and to improve screening. These efforts have also targeted underserved areas and are focused on reducing disparities in access.
肺癌仍然是美国癌症相关死亡率最高的疾病。虽然它是第三大确诊癌症,但发现时往往已是晚期。I 期肺癌的存活率超过 70%,而 IV 期肺癌的五年存活率不到 10%。多年来,人们一直在研究如何在早期发现肺癌,以便更有效地治疗。这些方法包括定期胸部 X 光检查(CXR)和痰液样本。遗憾的是,这些检测方式并未显示出任何益处。2011 年,全国肺筛查试验的数据公布后,情况发生了改变。这项具有里程碑意义的试验最终表明,每年对有严重吸烟史的患者进行一次低辐射剂量胸部计算机断层扫描(LDCT)可将肺癌相关死亡率降低 20%。这些结果推动了全国范围内加强肺癌筛查的努力。虽然在全国范围内接受筛查的符合条件的患者人数仍然不多,但各州和地方正在做出巨大努力,以提高人们的认识并改进筛查工作。这些努力还以服务不足的地区为目标,重点是减少获得筛查机会方面的差距。
{"title":"Lung Cancer Screening: Early Detection Decreases Mortality.","authors":"Brian Nam, Danny Hamm, Nora Katurakes, Charles Mulligan","doi":"10.32481/djph.2024.08.07","DOIUrl":"https://doi.org/10.32481/djph.2024.08.07","url":null,"abstract":"<p><p>Lung cancer remains the number one cancer related mortality in the United States . While it is the third most diagnosed cancer, it is often found at an advanced stage. Survival rates for stage I lung cancer are above 70% while survival rates for stage IV lung cancer are less than 10% at five years. Methods to detect lung cancer at an earlier stage when it can be more effectively treated have been investigated for many years. These included regular chest x-rays (CXRs) and sputum samples. Unfortunately, these testing modalities did not show any benefit. This changed in 2011 when data from the National Lung Screening Trial were published. This landmark trial showed conclusively that a low-radiation dose chest computed tomography scan (LDCT) performed annually in patients with a heavy smoking history reduced lung cancer related mortality by 20%. These results have led to a nationwide effort to increase lung cancer screening. While the number of eligible patients that are being screened on a national level remains modest, significant efforts are being made at the state and local levels to increase awareness and to improve screening. These efforts have also targeted underserved areas and are focused on reducing disparities in access.</p>","PeriodicalId":72774,"journal":{"name":"Delaware journal of public health","volume":"10 3","pages":"22-24"},"PeriodicalIF":0.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11356585/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-28eCollection Date: 2024-08-01DOI: 10.32481/djph.2024.08.11
Scott D Siegel
While Black and White women are diagnosed with breast cancer (BC) at similar rates, Black women die from BC at a 40% higher rate. This disparity is even more pronounced for younger Black women, who die from BC at nearly twice the rate as younger White women. Black-White differences in BC mortality are largely attributable to health care and tumor biology factors. Black women face greater barriers to accessing BC screening and are twice as likely to be diagnosed with the aggressive triple-negative breast cancer (TNBC) subtype. Delaware leads the US for the incidence of late-stage BC diagnosed among younger women and TNBC. This commentary begins with a discussion of precision public health, an emerging framework that builds on and complements recent advances in precision medicine. Next, a new precision public health initiative designed to reduce BC disparities in Delaware by targeting local hotspots with prevention interventions is presented. Finally, next steps are considered for implementation, evaluation, and new research activities.
虽然黑人和白人妇女被诊断出乳腺癌(BC)的比例相似,但黑人妇女死于乳腺癌的比例却高出 40%。这种差异在年轻的黑人女性中更为明显,她们死于乳腺癌的比例几乎是年轻白人女性的两倍。黑人与白人在 BC 死亡率上的差异主要归因于医疗保健和肿瘤生物学因素。黑人妇女在接受乳腺癌筛查方面面临更多障碍,被诊断为侵袭性三阴性乳腺癌(TNBC)亚型的可能性是白人妇女的两倍。特拉华州年轻女性晚期乳腺癌和 TNBC 的发病率在全美遥遥领先。本评论首先讨论了精准公共卫生,这是一个新兴的框架,它建立在精准医学最新进展的基础上,并与之相辅相成。接下来,介绍了一项新的精准公共卫生倡议,该倡议旨在通过针对当地热点采取预防干预措施来减少特拉华州 BC 的差异。最后,考虑了下一步的实施、评估和新的研究活动。
{"title":"Reducing Breast Cancer Disparities with Precision Public Health: A New Strategy to Improve Prevention and Advance Health Equity in Delaware Hotspots.","authors":"Scott D Siegel","doi":"10.32481/djph.2024.08.11","DOIUrl":"https://doi.org/10.32481/djph.2024.08.11","url":null,"abstract":"<p><p>While Black and White women are diagnosed with breast cancer (BC) at similar rates, Black women die from BC at a 40% higher rate. This disparity is even more pronounced for younger Black women, who die from BC at nearly twice the rate as younger White women. Black-White differences in BC mortality are largely attributable to health care and tumor biology factors. Black women face greater barriers to accessing BC screening and are twice as likely to be diagnosed with the aggressive triple-negative breast cancer (TNBC) subtype. Delaware leads the US for the incidence of late-stage BC diagnosed among younger women and TNBC. This commentary begins with a discussion of precision public health, an emerging framework that builds on and complements recent advances in precision medicine. Next, a new precision public health initiative designed to reduce BC disparities in Delaware by targeting local hotspots with prevention interventions is presented. Finally, next steps are considered for implementation, evaluation, and new research activities.</p>","PeriodicalId":72774,"journal":{"name":"Delaware journal of public health","volume":"10 3","pages":"46-50"},"PeriodicalIF":0.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11356581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-28eCollection Date: 2024-08-01DOI: 10.32481/djph.2024.08.03
{"title":"American Cancer Society Annual Cancer Statistics 2024 Shows Drop in Cancer Mortality but Increasing Incidence for Six of the Top Ten Cancers.","authors":"","doi":"10.32481/djph.2024.08.03","DOIUrl":"https://doi.org/10.32481/djph.2024.08.03","url":null,"abstract":"","PeriodicalId":72774,"journal":{"name":"Delaware journal of public health","volume":"10 3","pages":"6-7"},"PeriodicalIF":0.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11356587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-08-28eCollection Date: 2024-08-01DOI: 10.32481/djph.2024.08.08
Dawn Hollinger, Sumitha Nagarajan, Diane Ng, Wilhelmina Ross, Hayley Little, Helen Arthur
Objective: To describe the Delaware Cancer Registry (DCR)'s participation in the National Cancer Institute (NCI)/North American Association of Central Cancer Registries (NAACCR) Zone Design Project to create sub-county geographic areas ("zones") for use in cancer reporting and geospatial analysis.
Methods: DCR and other stakeholders reviewed up to ten unique zone configurations for each of Delaware's three counties. The zone configurations were created using AZTool and were set to optimize three objectives: create zones that have a minimum and target population of 50,000; are homogenous based on the variables of percent minority, percent below poverty, and percent urban; and are as compact as possible. The DCR sent a survey to stakeholders to provide input on their preferred zone configuration for each county. Following the final selection of zones, the DCR utilized the geographies for calculating overall and late-stage breast cancer incidence statistics and created choropleth maps to visualize the rates by quintiles.
Results: The final selections resulted in a total of 15 zones for Delaware, with three in Kent County, nine in New Castle County, and three in Sussex County. The zones ranged in population size from 54,013 to 67,693 people. Zones with higher late-stage breast cancer incidence rates included those near the areas of Wilmington, Middletown, and between Milford and Georgetown. Comparing results of overall breast cancer incidence rates by zone with late-stage rates by zone, there were areas that had lower relative overall breast cancer incidence rates but were relatively higher for late-stage rates by zones or vice versa.
Conclusions: Aggregating census tracts into zones allows for reporting reliable cancer rates at sub-county levels, which is instrumental in conveying meaningful information about regional cancer trends to stakeholders and the public. Delaware will be able to utilize zone-level cancer information to provide targeted interventions and outreach initiatives.
{"title":"Development of Sub-County Cancer Reporting Zones in Delaware and Example Use Case for Targeted Interventions.","authors":"Dawn Hollinger, Sumitha Nagarajan, Diane Ng, Wilhelmina Ross, Hayley Little, Helen Arthur","doi":"10.32481/djph.2024.08.08","DOIUrl":"https://doi.org/10.32481/djph.2024.08.08","url":null,"abstract":"<p><strong>Objective: </strong>To describe the Delaware Cancer Registry (DCR)'s participation in the National Cancer Institute (NCI)/North American Association of Central Cancer Registries (NAACCR) Zone Design Project to create sub-county geographic areas (\"zones\") for use in cancer reporting and geospatial analysis.</p><p><strong>Methods: </strong>DCR and other stakeholders reviewed up to ten unique zone configurations for each of Delaware's three counties. The zone configurations were created using AZTool and were set to optimize three objectives: create zones that have a minimum and target population of 50,000; are homogenous based on the variables of percent minority, percent below poverty, and percent urban; and are as compact as possible. The DCR sent a survey to stakeholders to provide input on their preferred zone configuration for each county. Following the final selection of zones, the DCR utilized the geographies for calculating overall and late-stage breast cancer incidence statistics and created choropleth maps to visualize the rates by quintiles.</p><p><strong>Results: </strong>The final selections resulted in a total of 15 zones for Delaware, with three in Kent County, nine in New Castle County, and three in Sussex County. The zones ranged in population size from 54,013 to 67,693 people. Zones with higher late-stage breast cancer incidence rates included those near the areas of Wilmington, Middletown, and between Milford and Georgetown. Comparing results of overall breast cancer incidence rates by zone with late-stage rates by zone, there were areas that had lower relative overall breast cancer incidence rates but were relatively higher for late-stage rates by zones or vice versa.</p><p><strong>Conclusions: </strong>Aggregating census tracts into zones allows for reporting reliable cancer rates at sub-county levels, which is instrumental in conveying meaningful information about regional cancer trends to stakeholders and the public. Delaware will be able to utilize zone-level cancer information to provide targeted interventions and outreach initiatives.</p>","PeriodicalId":72774,"journal":{"name":"Delaware journal of public health","volume":"10 3","pages":"26-29"},"PeriodicalIF":0.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11356584/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: American College of Surgeons Commission on Cancer (CoC) quality measures are used to monitor and evaluate metrics among their CoC-accredited programs, which include seven of Delaware's hospitals. The Delaware Department of Health and Social Services, Division of Public Health (DPH) also utilizes these metrics to monitor and evaluate Delaware's overall performance on these standards of care as it relates to the health care provided to cancer patients.
Methods: Delaware Cancer Registry (DCR) cases diagnosed in 2018 and 2019 were selected and were analyzed separately to calculate results for each selected measure by year: HT, nBX, LNoSurg, and RECRTCT.
Results: Results of the analysis showed that three out of the four CoC quality measures evaluated met the CoC standard of care for both 2018 and 2019 data. The three measures that met the CoC standards for 2018 were HT (90.4%), nBX (87.6%), and LNoSurg (93.3%). The RECRTCT measure did not meet the CoC standard for 2018 data with 71.4%. All four measures evaluated met the CoC standards for 2019 (HT - 91.6%; nBX - 85.2%; LNoSurg - 92.7%; RECRTCT - 92.3%).
Discussion: A majority of cases assessed met the CoC quality measure standards, meeting standards of cancer care and treatment. More discovery work needs to be done to assess the RECRTCT metric to explore reasons why cases did not meet the CoC quality measure standards. There was notable improvement seen for the HT measure over time, where cases had not met the CoC standard in previous years.
Public health implications: When CoC quality measures are met, medical providers can ensure patients receive effective and targeted cancer care. This practice ultimately saves resources, reduces cancer burden, impacts survival, and improves public health outcomes.
导言:美国外科医生学会癌症委员会(CoC)的质量衡量标准被用于监测和评估其CoC认证项目的各项指标,其中包括特拉华州的七家医院。特拉华州卫生和社会服务部公共卫生司(Department of Health and Social Services, Division of Public Health, DPH)也利用这些指标来监测和评估特拉华州在这些医疗标准方面的整体表现,因为这与为癌症患者提供的医疗服务有关:选取特拉华州癌症登记处(DCR)在 2018 年和 2019 年诊断的病例,并分别进行分析,计算出各年所选指标的结果:HT、nBX、LNoSurg 和 RECRTCT.结果:分析结果显示,在评估的四项CoC质量措施中,有三项在2018年和2019年的数据中均达到了CoC护理标准。2018 年达到 CoC 标准的三项措施分别是 HT(90.4%)、nBX(87.6%)和 LNoSurg(93.3%)。在 2018 年的数据中,RECRTCT 指标未达到 CoC 标准,仅为 71.4%。所有四项评估措施均符合 2019 年的 CoC 标准(HT - 91.6%;nBX - 85.2%;LNoSurg - 92.7%;RECRTCT - 92.3%):讨论:大多数评估病例符合CoC质量衡量标准,达到了癌症护理和治疗标准。在评估 RECRTCT 指标时,需要做更多的探索工作,以探究病例未达到 CoC 质量衡量标准的原因。随着时间的推移,前几年未达到 CoC 标准的 HT 指标有了明显改善:当达到 CoC 质量衡量标准时,医疗服务提供者可确保患者获得有效且有针对性的癌症护理。这种做法最终可节省资源、减轻癌症负担、影响生存率并改善公共卫生成果。
{"title":"Evaluating Quality of Cancer Care in Delaware using Commission on Cancer (CoC) Quality Measures, 2018-2019.","authors":"Wilhelmina Ross, Diane Ng, Hayley Little, Sumitha Nagarajan, Paulette Robinson-Wilkerson, Dawn Hollinger","doi":"10.32481/djph.2024.08.04","DOIUrl":"https://doi.org/10.32481/djph.2024.08.04","url":null,"abstract":"<p><strong>Introduction: </strong>American College of Surgeons Commission on Cancer (CoC) quality measures are used to monitor and evaluate metrics among their CoC-accredited programs, which include seven of Delaware's hospitals. The Delaware Department of Health and Social Services, Division of Public Health (DPH) also utilizes these metrics to monitor and evaluate Delaware's overall performance on these standards of care as it relates to the health care provided to cancer patients.</p><p><strong>Methods: </strong>Delaware Cancer Registry (DCR) cases diagnosed in 2018 and 2019 were selected and were analyzed separately to calculate results for each selected measure by year: HT, nBX, LNoSurg, and RECRTCT.</p><p><strong>Results: </strong>Results of the analysis showed that three out of the four CoC quality measures evaluated met the CoC standard of care for both 2018 and 2019 data. The three measures that met the CoC standards for 2018 were HT (90.4%), nBX (87.6%), and LNoSurg (93.3%). The RECRTCT measure did not meet the CoC standard for 2018 data with 71.4%. All four measures evaluated met the CoC standards for 2019 (HT - 91.6%; nBX - 85.2%; LNoSurg - 92.7%; RECRTCT - 92.3%).</p><p><strong>Discussion: </strong>A majority of cases assessed met the CoC quality measure standards, meeting standards of cancer care and treatment. More discovery work needs to be done to assess the RECRTCT metric to explore reasons why cases did not meet the CoC quality measure standards. There was notable improvement seen for the HT measure over time, where cases had not met the CoC standard in previous years.</p><p><strong>Public health implications: </strong>When CoC quality measures are met, medical providers can ensure patients receive effective and targeted cancer care. This practice ultimately saves resources, reduces cancer burden, impacts survival, and improves public health outcomes.</p>","PeriodicalId":72774,"journal":{"name":"Delaware journal of public health","volume":"10 3","pages":"8-11"},"PeriodicalIF":0.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11356582/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}